The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biomedical Research Key to Advancing Clinical Care for Rheumatic Diseases

Biomedical Research Key to Advancing Clinical Care for Rheumatic Diseases

January 19, 2017 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Pressmaster/shutterstock.com

Pressmaster/shutterstock.com

WASHINGTON, D.C.—The importance of biomedical research to advancing clinical care with the ultimate goal of improving patients’ lives was on display during an ACR Discovery 2016 plenary session at the 2016 ACR/ARHP Annual Meeting.

You Might Also Like
  • Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases
  • New Findings on Rheumatic Drug Therapies among Patients with Ankylosing Spondylitis, Gout, SLE
  • Quality Measures Used to Assess Care, Improve Outcomes in Children, Adults with Rheumatic Diseases
Explore This Issue
January 2017
Also By This Author
  • In 2022, Advocacy 101 Returns to Washington, D.C.

The session offered new ways to think about and treat select rheumatologic diseases, including research showing for the first time the efficacy of a steroid-sparing medication for giant cell arteritis (GCA), research suggesting that statins may lower mortality risk in patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA) and research showing the importance of normalizing uric acid levels to improve renal function in patients with chronic kidney disease (CKD).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Steroid-Sparing Medication for GCA

“The era of unending glucocorticoid treatment with no viable alternative is over,” said John H. Stone, MD, MPH, director of clinical rheumatology and the Edward A. Fox Chair in Medicine at the Massachusetts General Hospital, who presented the findings of the GiACTA trial.

The GiACTA trial, the largest trial ever conducted of patients with GCA, enrolled 251 patients from 14 countries and 76 sites for 22 months to evaluate the efficacy and safety of tocilizumab for patients with GCA. Dr. Stone said that GiACTA is also the first trial for any disease to employ a blinded, variable-dose, steroid-tapering regimen.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The trial compared the efficacy of four different treatment arms for patients with GCA: 26-week prednisone taper (PBO + 26; n=50), 52-week prednisone taper (PBO + 52; n=50), tocilizumab 162 mg once weekly + PBO + 26 (TCZ QW; n=100), and tocilizumab 162 mg once every two weeks + PBO + 26 (TCZ Q2W; n=50).

At 52 weeks, the study showed significantly greater sustained remission in patients treated with tocilizumab compared with prednisone (see Table ).

TABLE 1: Primary Outcome: Sustained Remission from Week 12 to Week 52

TABLE 1: Primary Outcome: Sustained Remission from Week 12 to Week 52

The most surprising finding of the study, according to Dr. Stone, was the poor results in the patients treated with prednisone only. “I think most rheumatologists will find it surprising that the therapy we have regarded as the standard of care—that has been the standard of care for many decades—fared so poorly,” he said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Along with the significant benefit to adding tocilizumab, the study found no significant differences in adverse events among the treatment arms. “In fact, patients in the steroid-only groups were more likely to experience more than one serious adverse event than were those in the tocilizumab groups,” he said, adding that this “underscores the major contribution of glucocorticoids to toxicity in this disease.”

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Spondyloarthritis Tagged With: 2016 ACR/ARHP Annual Meeting, American College of Rheumatology, Ankylosing Spondylitis, biomedical research, chronic kidney disease, Clinical, conditions, Giant Cell Arteritis, outcome, patient care, Psoriatic Arthritis, Rheumatic Disease, Statin, Steroid, TreatmentIssue: January 2017

You Might Also Like:
  • Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases
  • New Findings on Rheumatic Drug Therapies among Patients with Ankylosing Spondylitis, Gout, SLE
  • Quality Measures Used to Assess Care, Improve Outcomes in Children, Adults with Rheumatic Diseases
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)